Curative strategies in acute myeloid leukemia in younger adults

Apply

Curative strategies in acute myeloid leukemia in younger adults

Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2005, Vol 22, Issue 3

Abstract

The treatment of acute myeloid leukemia (ΑML) generally involves the administration of cytotoxic chemotherapy to eradicate the malignant cells, which permits restoration of normal hematopoiesis by normal residual stem cells. The outcome for adults with AML depends not only on the age of the patient but also on the intensity of post-remission therapy and on the biologic characteristics of the disease, including the karyotype and the expression of the multidrug resistant (mdr) phenotype. The French-American-British (FAB) classification allows the uniformity of diagnosis at morphologic subtypes of AML. The new WHO classification correlates morphology, cytochemistry, immunophenotype, karyotype, and molecular genetics with clinical features. Improvements in outcome have been achieved primarily because of better supportive care, post-remission intensive chemotherapy (IC), autologous stem cell transplantation (auto-SCT) or allogeneic stem cell transplantation (allo-SCT). Patients with standard-risk disease have traditionally been referred for a matched sibling allograft if a donor is available and the patient's performance status is adequate. In recent years, chemotherapy postremission has improved outcome, with 50% 5-year overall survival (OS) and 40% disease-free survival

Authors and Affiliations

N. ANAGNOSTOPOULOS

Keywords

Role of incretin, incretin analogues and dipeptidyl peptidase 4 inhibitors<br /> in the pathogenesis and treatment of diabetes mellitus

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gut-derived incretin hormones that stimulate insulin and suppress glucagon secretion, inhibit gastric emptying, and reduce appeti...

EP ID EP133945
DOI -
Views 106
Downloads 0